Management of macular edema secondary to retinal vein occlusions

Expert Review of Ophthalmology

Volumn 6, Issue 5, 2011, Pages 557-564

  Ciardella, Antonio P ^a   Morara, Mariachiara ^a   Pichi, Francesco ^b   Alkabes, Micol ^b   Romano, Simona ^b   Nucci, Paolo ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b San Giuseppe Hospital Eye Clinic   (Italy)

Author keywords

Edema; Intravitreal anti VEGF; Intravitreal steroids; Vein occlusion

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; GLUCOCORTICOID; PLACEBO; RANIBIZUMAB; TRIAMCINOLONE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN TRAP EYE;

BINDING AFFINITY; BRANCH RETINAL VEIN OCCLUSION; CATARACT; CENTRAL RETINA VEIN OCCLUSION; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE DISEASE; EYE PAIN; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LASER COAGULATION; MONOTHERAPY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PATHOGENESIS; PROGNOSIS; PROTEIN SYNTHESIS INHIBITION; RETINA DETACHMENT; RETINA MACULA EDEMA; RETINA MACULA HEMORRHAGE; RETINA TEAR; RETINA VEIN OCCLUSION; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

EID: 80053956588     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/eop.11.59     Document Type: Review

References (42)

1. Cugati S, Wang JJ. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology 114, 520-524 (2007). (Pubitemid 46282956)
2. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountais Eye Study. Arch. Ophthalmol. 114, 1243-1247 (1996). (Pubitemid 26338856)
3. Hayreh SS. Classification of central retinal vein occlusion. Ophthalmology 90(5), 458-474 (1983). (Pubitemid 13059774)
4. Rogers S, McIntosh RL, Cheung N et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117(2), 313.e1-319.e1 (2010).
5. Parodi MB, Bandello F. Branch retinal vein occlusion: classification and treatment. Ophthalmologica 223(5), 298-305 (2009).
6. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr. Eye Res. 33(2), 111-131 (2008). (Pubitemid 351302200)
7. McIntosh RL, Rogers SL, Lim L et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117(6), 1113.e15-1123.e15 (2010).
8. Sperduto RD, Hiller R, Chew E et al. Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion: the eye disease case-control study. Ophthalmology 105(5), 765-771 (1998).
9. No authors listed. Risk factors for central retinal vein occlusion. The eye disease case-control study group. Arch. Ophthalmol. 114(5), 545-554 (1996).
10. Greer DV, Constable IJ, Cooper RL. Macular oedema and retinal branch vein occlusion. Aust. J. Ophthalmol. 8, 207-209 (1980). (Pubitemid 11251129)
11. Decroos FC, Fekrat S. The natural history of retinal vein occlusion: what do we really know? Am. J. Ophthalmol. 151(5), 739-741.e2 (2011).
12. No authors listed. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch. Ophthalmol. 115(4), 486-491 (1997).
13. Gewaily D, Greenberg PB. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst. Rev. 1, CD007324 (2009).
14. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia: the Blue Mountains Eye Study. Arch. Ophthalmol. 114, 1243-1247 (1996). (Pubitemid 26338856)
15. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans. Am. Ophthalmol. Soc. 98, 133-143 (2000). (Pubitemid 32059501)
16. Frangieh GT, Green WR, Barraquer-Somers E, Finkelstein D. Histopathologic study of nine branch retinal vein occlusions. Arch. Ophthalmol. 100, 1132-1140 (1982). (Pubitemid 12078142)
17. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr. Eye Res. 33, 111-131 (2008). (Pubitemid 351302200)
18. Antonetti DA, Barber AJ, Khin S et al. Penn State Retina Research Group. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes 47, 1953-1959 (1998). (Pubitemid 28549205)
19. Campochiaro PA, Hafiz G, Shah SM et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol. Ther. 16, 791-799 (2008). (Pubitemid 351426182)
20. No authors listed. Branch Vein Occlusion Study Group: argon laser photocoagulation for macular edema in branch vein occlusion. Am. J. Ophthalmol. 98, 271-282 (1984).
21. The SCORE study research group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion. The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5. Arch. Ophthalmol. 127, 1101-1114 (2009).
22. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to branch retinal vein occlusion. The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 6. Arch. Ophthalmol. 127, 1115-1128 (2009).
23. Brown DM, Campochiaro PA, Singh RP et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a Phase III study. Ophthalmology 117, 1124-1233 (2010).
24. Campochiaro PA, Heier JS, Feiner L et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a Phase III study. Ophthalmology 117, 1102-1112 (2010).
25. Haller JA, Bandello F, Belfort R et al. Randomized, sham controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117, 1134-1146 (2010).
26. Aiello LP, Bursell SE, Clermont A et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective b-isoform-selective inhibitor. Diabetes 46(9), 1473-1480 (1997). (Pubitemid 27369086)
27. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occluding and zonula occluden 1: a potential mechanism for vascular permeability in diabetic retinopathy and tumors. J. Biol. Chem. 274(33), 23463-23467 (1999).
28. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor (VPF) that promotes accumulation of ascites fluid. Science 219(4587), 983-985 (1983).
29. Vinores SA, Youssri AI, Luna JD et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol. Histopathol. 12(1), 99-109 (1997). (Pubitemid 27106924)
30. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 105(3), 412-416 (1998). (Pubitemid 28125092)
31. Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 57(4), 1026-1033 (2008).
32. Wang K, Wang Y, Gao L, Li X, Li M, Guo J. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol. Pharm. Bull. 31(8), 1541-1546 (2008).
33. Lee HB, Pulido JS, McCannel CA, Buettner H. Role of inflammation in retinal vein occlusion. Can. J. Ophthalmol. 42(1), 131-133 (2007). (Pubitemid 46408910)
34. Moradian S, Faghihi H, Sadeghi B et al. Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1). Graefes Arch. Clin. Exp. Ophthalmol. 249(2), 193-200 (2011).
35. Cekiç O, Cakir M, Yazici AT, Alagöz N, Bozkurt E, Faruk Yilmaz O. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion. Curr. Eye Res. 35(10), 925-929 (2010).
36. Ip MS, Oden NL, Scott IU et al. SCORE Study Investigator Group. SCORE Study report 3: study design and baseline characteristics. Ophthalmology 116, 1770-1777 (2009).
37. Brown DM, Campochiaro PA, Singh RP et al.; CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117(6), 1124-1133.e1 (2010).
38. Campochiaro PA, Heier JS, Feiner L et al.; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a Phase III study. Ophthalmology 117(6), 1102-1112.e1 (2010).
39. Haller JA, Bandello F, Belfort R Jr et al.; Ozurdex GENEVA Study Group. Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein Occlusion Twelve-Month Study Results. Ophthalmology DOI: 10.1016/j. ophtha.2011.05.014 (2011) (Epub ahead of print).
40. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br. J. Ophthalmol. 92(5), 667-668 (2008). (Pubitemid 351684178)
41. Beck RW, Maguire MG, Bressler NM, et al. Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology 114, 1804-1809 (2007). (Pubitemid 47483941)
42. Wittes J, Downs M. Outcome measures to assess efficacy of treatments for age-related macular degeneration. Ophthalmology 116, S8-S14 (2009).